Uncategorized
CABERNET trial: Epimacular brachytherapy inferior to ranibizumab monotherapy
Ranibizumab injections alone yielded better anatomic outcomes than epimacular brachytherapy combined with as-needed doses of ranibizumab in eyes with age-related macular degeneration, according to a study. The CNV secondary to AMD treated with BEta RadiatioN Epiretinal Therapy (CABERNET) trial, a multicenter randomized study, included 227 patients who underwent epimacular brachytherapy (EMBT), two monthly intravitreal injections of 0.5 mg ranibizumab (Lucentis, Genentech) and subsequent as-needed (PRN) doses of ranibizumab.